Common Myths and Misconceptions That Sidetrack Parkinson Disease Treatment, to the Detriment of Patients
- 1 October 2020
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 95 (10) , 2225-2234
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Cheaper, Simpler, and Better: Tips for Treating Seniors With Parkinson DiseaseMayo Clinic Proceedings, 2011
- Rasagiline, Parkinson neuroprotection, and delayed-start trialsNeurology, 2010
- The Concept of Continuous Dopaminergic Stimulation: What We Should Consider when Starting Parkinson’s Disease TreatmentNeurodegenerative Diseases, 2010
- Levodopa‐dyskinesia incidence by age of Parkinson's disease onsetMovement Disorders, 2005
- The substantia nigra of the human brainBrain, 1999
- The effect of deprenyl and levodopa on the progression of Parkinson's diseaseAnnals of Neurology, 1995
- Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?Brain Research, 1994
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991
- Controlled-Release Sinemet (CR-4): A Double-Blind Crossover Study in Patients With Fluctuating Parkinson's DiseaseMayo Clinic Proceedings, 1988
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984